Breda

High-End Performance Meets Style and Comfort in Kichler Lighting's New Ceiling Fans Décor Release

Retrieved on: 
Tuesday, October 3, 2023
Lighting, Nickel, The Home Depot, Ceiling, Light, CCT, ABS, LED, Collection, Nani, UV, Lowe's, Relaxation, Environment, Breda, First Ever, Heating, ventilation, and air conditioning, Cosmetics

SOLON, Ohio, Oct. 3, 2023 /PRNewswire/ -- Kichler Lighting LLC, a leader in innovative lighting and ceiling fans, gives any space a breath of fresh air with its new Ceiling Fans Décor. This introduction of four new families is engineered for performance and comfort while boasting sophisticated, on-trend designs.

Key Points: 
  • SOLON, Ohio, Oct. 3, 2023 /PRNewswire/ -- Kichler Lighting LLC , a leader in innovative lighting and ceiling fans, gives any space a breath of fresh air with its new Ceiling Fans Décor.
  • This introduction of four new families is engineered for performance and comfort while boasting sophisticated, on-trend designs.
  • "Our latest Ceiling Fans Décor release bridges the gap between the delivery of cooling comfort and elevated design," says Kichler Lighting's Product Manager, Ceiling Fans, Scott Williams.
  • Whether that be luxe, modern, or global, these fans are designed to meet you where you are and take your space to the next level."

Partners Bancorp Reports Results of Operations for the Second Quarter 2023

Retrieved on: 
Monday, July 31, 2023
Liberty Bell Bank, Lender option borrower option, Federal Home Loan Banks, Insurance, Maintenance, Total, Partnership, OceanFirst Bank, Small Business Administration, Tax, Paycheck Protection Program, FDIC, Sale, PPP, ATM, Disposable household and per capita income, Bank, LINK, Small business, Growth, Depreciation, Forgiveness, Environment, Breda, Cryptocurrency, Airline, Rare-earth element, Real estate, Renting, Life insurance, Video game, Delmarva Peninsula, Washington metropolitan area

While the Company’s net interest margin for the second quarter of 2023 improved by 0.84% compared to the same period of 2022, we experienced a decline of 0.11% when compared to the first quarter of 2023.

Key Points: 
  • While the Company’s net interest margin for the second quarter of 2023 improved by 0.84% compared to the same period of 2022, we experienced a decline of 0.11% when compared to the first quarter of 2023.
  • Interest Income and Expense – Three Months Ended June 30, 2023 and 2022
    Net interest income in the second quarter of 2023 increased by $2.0 million, or 15.1%, when compared to the second quarter of 2022.
  • Other income in the second quarter of 2023 decreased by $378 thousand, or 26.0%, when compared to the second quarter of 2022.
  • Other expenses in the second quarter of 2023 increased by $978 thousand, or 9.9%, when compared to the second quarter of 2022.

ACURE Appoints Carina Breda as Chief Executive Officer

Retrieved on: 
Friday, June 3, 2022
Leadership, Company, Marketing, LLC, Hair, CEO, Breda, Awareness, Senior, Revlon, Industry, Nature, Skin, Wella, Communication, Global marketing, Management, Cosmetics

FORT LAUDERDALE, Fla., June 3, 2022 /PRNewswire/ -- Better Planet Brands, LLC d/b/a ACURE, a well-established brand in the natural clean beauty industry within the United States, today announced that Carina Breda has been named as Chief Executive Officer and will assume day-to-day leadership of the Company.

Key Points: 
  • FORT LAUDERDALE, Fla., June 3, 2022 /PRNewswire/ -- Better Planet Brands, LLC d/b/a ACURE, a well-established brand in the natural clean beauty industry within the United States, today announced that Carina Breda has been named as Chief Executive Officer and will assume day-to-day leadership of the Company.
  • Prior to that, Breda served in several senior marketing roles for a number of companies that included Revlon, Orly International and Wella.
  • "Carina is the right leader for ACURE at this time," said Jon Guerra.
  • ACURE products for skin, hair and body are distributed nationally through many prominent retailers, both in-store and on-line.

argenx Announces Publication of Translational Data of Efgartigimod in Autoimmune Skin Blistering Diseases

Retrieved on: 
Thursday, May 19, 2022
Degenerative disease, Risk, No, Company, Pemphigus foliaceus, Annual general meeting, Neuromuscular Disorders, Immunoglobulin G, PV, Pemphigus vulgaris, Infection, Euronext, Patient, Biology, SID, Antibody, Quality of life, BP, Research, Journal of the American Academy of Dermatology, FC, Instagram, IIP, Breda, Neutrophil, Lymphocyte, Monocyte, Skin, LinkedIn, Twitter, Recurrent corneal erosion, Society, Acantholysis, Red blood cell, Pharmaceutical industry, Vaccine, Cell, Neonatal Fc receptor, Dermatology, Pemphigus, Pemphigus

The novel translational data, along with previously published translational data in Cells , will also be presented in a symposium today at the Society for Investigative Dermatology (SID) Annual Meeting at 7:30am PT.

Key Points: 
  • The novel translational data, along with previously published translational data in Cells , will also be presented in a symposium today at the Society for Investigative Dermatology (SID) Annual Meeting at 7:30am PT.
  • Efgartigimod is being investigated in several autoimmune diseases known to be mediated by disease-causing IgG antibodies, including neuromuscular disorders, blood disorders, and skin blistering diseases.
  • argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases.
  • The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises.

argenx Reports Full Year 2021 Financial Results and Provides Fourth Quarter Business Update

Retrieved on: 
Thursday, March 3, 2022
Patient, Pharmacokinetics, Â, Clinical trial, Adult, Myositis, Neonatal Fc receptor, Microdeletion syndrome, Dermatomyositis, Breda, Safety, FDA, Program, Ministry of Health, Labour and Welfare, Time, GMG, SIMPLE, Degenerative disease, Euronext, MMN, Acetylcholine receptor, FC, SC, MuSK protein, Multifocal motor neuropathy, Pharmaceutical industry, Health

VYVGART (efgartigimod alfa-fcab) approved in the U.S. and Japan as the first-and-only neonatal Fc receptor (FcRn) blocker; U.S. commercial launch underway

Key Points: 
  • VYVGART (efgartigimod alfa-fcab) approved in the U.S. and Japan as the first-and-only neonatal Fc receptor (FcRn) blocker; U.S. commercial launch underway
    Breda, the Netherlands argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today reported financial results for the full year 2021 and provided a fourth quarter business update.
  • 2021 was a transformational year for argenx, culminating with the FDA approval of VYVGART, our first-in-class FcRn blocker, in December.
  • We carried this momentum into 2022 with the official U.S. launch of VYVGART and the Japan approval.
  • In addition to executing the global commercial launch of VYVGART, we are primed to deliver several upcoming catalysts through our development pipeline in high-value autoimmune indications.

RoomRaccoon - The World's Number One Hotel Management System Now Available Across United States

Retrieved on: 
Tuesday, November 30, 2021
Cloud, Industry, General manager, Eye, Partnership, Booking.com, Assistant, Hotel

RoomRaccoon looks forward to expanding with our existing partners including Event Temple, Lightspeed, Expedia, and Ivvy.

Key Points: 
  • RoomRaccoon looks forward to expanding with our existing partners including Event Temple, Lightspeed, Expedia, and Ivvy.
  • As a team, we really understand the RoomRaccoon system," said Aimee Lawson, Assistant General Manager of Cloud Estate Boutique Hotel in Stellenbosch, South Africa.
  • RoomRaccoon is the secret weapon to successful hotel management, said Jayson Van Noordwyk, General Manager of OTwo Hotel in Cape Town, South Africa.
  • RoomRaccoon was voted the best Hotel Management System in 2020 and 2021 by hotel managers and industry experts on Hotel Tech Report.

argenx to Present at Upcoming Investor Conferences

Retrieved on: 
Wednesday, November 10, 2021
Euronext, Cancer, IIP, Twitter, Conference, LinkedIn, Degenerative disease, Animal, Vaccine

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.

Key Points: 
  • argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer.
  • Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines.
  • argenx is evaluating efgartigimod in multiple serious autoimmune diseases.
  • argenx is also advancing several earlier stage experimental medicines within its therapeutic franchises.

argenx Reports Third Quarter 2021 Financial Results and Provides Business Update

Retrieved on: 
Thursday, October 28, 2021
MSE, ITP, Annual general meeting, Yangon City Development Committee, Cancer, Disease, CIDP, Prescription Drug User Fee Act, Association, PDUFA, Chronic inflammatory demyelinating polyneuropathy, Organization, Partnership, Euronext, Patient, Pemphigus, Medison, Myositis, FDA, BLA, Food, GMG, DevOps, Review, Degenerative disease, MGFA, ADAPT, American Association, Food and Drug Administration, American Association of Neuromuscular & Electrodiagnostic Medicine, Protocol, AANEM, CMO, Myasthenia gravis, Electrodiagnostic medicine, Development, Consistency, Pharmaceutical industry

Breda, the Netherlands argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced its third quarter 2021 financial results and provided a business update and outlook for the remainder of the year.

Key Points: 
  • Breda, the Netherlands argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced its third quarter 2021 financial results and provided a business update and outlook for the remainder of the year.
  • This includes a first-in-class C2 inhibitor, ARGX-117, which is on track to begin the first Phase 2 trial in multifocal motor neuropathy patients by the end of this year.
  • Our growing commercial infrastructure along with our expanding pipeline ambitions provide considerable opportunity for argenx to deliver long-term, sustainable growth, concluded Mr. Van Hauwermeiren.
  • Additional data to be presented at upcoming Myasthenia Gravis Foundation of America (MGFA) Scientific Session.

argenx to Report Third Quarter 2021 Financial Results and Business Update on October 28, 2021

Retrieved on: 
Thursday, October 21, 2021
Degenerative disease, Euronext, CET, Investor, Cancer, Webcast, Pharmaceutical industry

Breda, the Netherlands argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Thursday, October 28, 2021 at 2:30 pm CET (8:30 am ET) to discuss its third quarter 2021 financial results and provide a business update.

Key Points: 
  • Breda, the Netherlands argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Thursday, October 28, 2021 at 2:30 pm CET (8:30 am ET) to discuss its third quarter 2021 financial results and provide a business update.
  • A webcast of the live call may be accessed on the Investors section of the argenx website at argenx.com/investors .
  • A replay of the webcast will be available on the argenx website for approximately one year following the call.
  • Please dial in 15 minutes prior to the live call.

argenx to Highlight Potential First-in-Class FcRn Antagonist Efgartigimod at Upcoming Neuromuscular Meetings

Retrieved on: 
Friday, October 8, 2021
Aurora, Treatment, Electrodiagnostic medicine, Degenerative disease, Myasthenia gravis, Euronext, Subgroup analysis, CIDP, AANEM, Comorbidity, MDT, MGFA, GMG, Quality of life, Cancer, United, ADAPT, Practice, American Association, Association, American Association of Neuromuscular & Electrodiagnostic Medicine, Efficacy, CO, Time, Conditional sentence, Review, Neurology, Annual general meeting, Pharmaceutical industry, Fireworks

The data will be presented at two upcoming neuromuscular meetings: the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting on October 13-16, 2021 in Aurora, CO and the virtual Myasthenia Gravis Foundation of America Scientific Session (MGFA) on October 30, 2021.

Key Points: 
  • The data will be presented at two upcoming neuromuscular meetings: the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting on October 13-16, 2021 in Aurora, CO and the virtual Myasthenia Gravis Foundation of America Scientific Session (MGFA) on October 30, 2021.
  • "The additional ADAPT data presented during these important neuromuscular forums strengthen our understanding of the value efgartigimod can offer as a potential treatment for people living with gMG.
  • Depth and consistency of disease score improvement, as well as a patient's ability to mount a vaccine response, are all key considerations for a treating physician," commented Wim Parys, M.D., Chief Medical Officer of argenx.
  • We will continue to listen to patients in uncovering the real-world burden associated with management of this debilitating, chronic disease."